FDA CBD Enforcement Policy Heads to White House Review
Advertisement
The federal government's long-awaited reckoning with the CBD market is finally taking shape. On March 13, the Food and Drug Administration quietly submitted a document titled "Cannabidiol (CBD) Products Compliance and Enforcement Policy" to the White House Office of Information and Regulatory Affairs (OIRA), setting the stage for what could become the most consequential regulatory action in the history of the hemp-derived cannabinoid industry.
Now, with meetings scheduled for April 1 and April 2 between the Office of Management and Budget and industry stakeholders, the clock is ticking on a multibillion-dollar market that has operated in a regulatory gray zone for nearly eight years.
Table of Contents
- What the FDA Submitted — and Why It Matters
- The April Meetings: Who's at the Table
- A Market in Regulatory Limbo
- What This Means for Consumers
- The Bigger Picture: November's Hemp THC Ban Looms
- What Happens Next
What the FDA Submitted — and Why It Matters
The submission marks the first time the FDA has advanced a formal enforcement framework specifically targeting CBD products since the 2018 Farm Bill [Quick Definition: The federal law that legalized hemp with less than 0.3% THC, creating the hemp CBD industry] legalized hemp. While the full text of the proposal remains confidential during the standard 90-day OIRA review period, industry observers and legal analysts have pieced together a picture of what the agency likely has in mind.
Based on previous FDA statements and enforcement letters, the policy is expected to address several critical areas: standardized labeling requirements to combat the rampant inaccuracy that has plagued the CBD market, contaminant controls including heavy metals and pesticide limits, CBD content caps per serving and per container, and measures specifically designed to reduce children's access to cannabinoid products.
The FDA has long maintained that CBD cannot legally be marketed as a dietary supplement or added to food, citing the prior approval of Epidiolex (a CBD-based pharmaceutical) as the basis for this position. Yet the agency's enforcement of this stance has been sporadic at best, limited to warning letters that many companies simply ignored.
"The Wild West era of CBD is coming to an end," said cannabis regulatory attorney Lauren Rudick of Harris Bricken. "What we're seeing is the FDA finally putting structure around a market that's been self-regulating — often poorly — for years."
The April Meetings: Who's at the Table
The first confirmed meeting, scheduled for April 1 at 3:00 PM, will include David Heldreth, CEO of Panacea Plant Sciences, a cannabis biotechnology company. Heldreth has indicated he plans to encourage the FDA to develop "more holistic guidance" around CBD that considers the full spectrum of cannabinoid products rather than treating CBD in isolation.
Additional meetings on April 2 are expected to include representatives from major CBD brands, hemp trade associations, and consumer advocacy groups. The meetings fall under Executive Order 12866 guidelines, which require OIRA to solicit stakeholder input during its review of significant regulatory actions.
The timing of these meetings is notable. They come just six weeks past the congressionally imposed deadline for the FDA to publish a list of all known cannabinoids naturally produced by Cannabis sativa L. — a requirement included in the November 2025 legislation that redefined hemp. The agency's failure to meet this deadline has drawn criticism from both industry groups and members of Congress.
A Market in Regulatory Limbo
The CBD market in the United States generates an estimated $5.3 billion in annual sales, according to Brightfield Group data, with products ranging from tinctures and gummies to topicals, beverages, and pet supplements. Yet studies have consistently shown that a significant portion of these products contain inaccurate CBD levels — sometimes dramatically so.
A 2025 Johns Hopkins analysis found that nearly 50 percent of tested CBD products contained THC levels exceeding the 0.3 percent legal limit, while many contained less CBD than advertised. These findings have strengthened the FDA's case for aggressive enforcement standards.
The regulatory uncertainty has also created an awkward collision with other federal initiatives. The Centers for Medicare and Medicaid Services (CMS) is preparing to launch a pilot program in April that would reimburse seniors up to $500 annually for CBD products — products that the FDA has technically never approved for any consumer use outside of Epidiolex.
"You have one arm of the federal government preparing to pay for CBD products while another arm is preparing to crack down on the very same products," noted Paul Shortino, a hemp policy analyst at the Brookings Institution. "It's the kind of contradiction that only cannabis policy in America can produce."
What This Means for Consumers
If the FDA's enforcement policy proceeds on the timeline suggested by the OIRA submission, a formal announcement could arrive by mid-June 2026. For consumers, the implications are significant.
Products that don't meet new labeling and testing standards could be pulled from shelves. Brands that have relied on vague health claims — a common practice in the CBD space — may face enforcement actions. And the overall quality of available CBD products should improve as companies invest in compliance.
However, consumer advocates worry that overly strict regulations could also drive up prices, limit product availability, and push consumers toward unregulated online markets.
The Bigger Picture: November's Hemp THC Ban Looms
The FDA's CBD enforcement push doesn't exist in a vacuum. It's unfolding against the backdrop of sweeping changes to federal hemp law scheduled to take effect on November 12, 2026. The new legislation redefines hemp to include total THC (including THCA) rather than just delta-9 THC, effectively banning most intoxicating hemp [Quick Definition: Hemp-derived products engineered to produce a psychoactive high]-derived products.
This means the CBD enforcement policy being reviewed at the White House will govern a dramatically different market by year's end — one where products containing significant levels of any THC compound will be illegal under federal law.
For the CBD industry, the next few months represent both a threat and an opportunity. Companies that embrace compliance early may find themselves well-positioned in a more regulated — and potentially more respected — marketplace. Those that don't may find the regulatory walls closing in from multiple directions.
What Happens Next
The OIRA review process typically takes 90 days, though extensions are common. During this period, additional stakeholder meetings may be scheduled, and the text of the policy could be revised based on feedback.
Industry groups, including the U.S. Hemp Roundtable and the Hemp Industries Association, have already signaled their intent to participate in the review process. Both organizations have advocated for "reasonable" CBD regulations that protect consumers without destroying the livelihoods of small hemp farmers and CBD manufacturers.
For now, the CBD market continues to operate under the same ambiguous rules that have governed it since 2018. But with the FDA's enforcement policy sitting on the White House's desk and April meetings just days away, the era of regulatory ambiguity may finally be drawing to a close.
Pull-Quote Suggestions:
"The CBD market in the United States generates an estimated $5.3 billion in annual sales, according to Brightfield Group data, with products ranging from tinctures and gummies to topicals, beverages, and pet supplements."
"Now, with meetings scheduled for April 1 and April 2 between the Office of Management and Budget and industry stakeholders, the clock is ticking on a multibillion-dollar market that has operated in a regulatory gray zone for nearly eight years."
"The Centers for Medicare and Medicaid Services (CMS) is preparing to launch a pilot program in April that would reimburse seniors up to $500 annually for CBD products — products that the FDA has technically never approved for any consumer use outside of Epidiolex."
Why It Matters: The FDA submitted its CBD compliance and enforcement policy to the White House for review. April meetings could reshape the $5B CBD market.